Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
CELEBRATION, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023. Neil succeeds Christal M.M. Mickle who has been serving as interim CEO and President since June 2023, and who will continue serving in her role as Chief Development Officer. Concurrently, the Company announced the effectiveness of Joseph B. Saluri’s previously announced retirement from the Board of Directors. Mr. Saluri’s valuable leadership has played a crucial role in shaping Zevra's growth since joining the Board in 2014. Mr. Saluri’s retirement is in accordance with the plan announced by the Company on May 8, 2023.
- CELEBRATION, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023.
- Mickle who has been serving as interim CEO and President since June 2023, and who will continue serving in her role as Chief Development Officer.
- I look forward to joining this talented team of professionals who are poised to accelerate our mission to deliver new therapies to the rare disease community,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
- The option and restricted stock units were granted as inducements material to the executive entering into employment with Zevra in accordance with Nasdaq Rule 5635(c)(4).